Advances in kidney cancer have occurred over the past decade, including the discovery of mutations in chromatin remodeling genes and genomic heterogeneity in clear cell renal cell carcinoma (ccRCC), altered metabolic patterns in ccRCC and papillary renal cell carcinoma and the approval of drugs for patients with ccRCC.